PFE vs MRNA: Pfizer vs Moderna Stock Comparison: AI Score, Valuation, Performance and Upside
Pfizer is a large diversified pharmaceutical company managing the post-COVID revenue normalization while building out ADC oncology through the Seagen acquisition; Moderna is a much smaller, more concentrated mRNA platform company still highly dependent on COVID vaccine revenue while racing to commercialise its pipeline. Pfizer is the defensive value position; Moderna is the higher-risk, higher-potential-reward platform bet.
Use this PFE vs MRNA comparison to choose between large-cap pharma value and mRNA platform optionality. Pfizer offers a high dividend yield and diversified revenue while navigating COVID headwinds; Moderna offers exposure to the mRNA platform's broader potential, anchored by a potentially landmark personalised cancer vaccine, at the cost of significant cash burn risk.
Human Wall Street analysts' price targets, typically implying a ~12-month view — a separate signal from this site's own AI Prediction Signal further down the page, which is a 5-/30-day machine-learning forecast based on price history alone.
- Want a high-dividend-yield large-cap pharma with a diversified product portfolio
- Value ADC oncology exposure through the Seagen acquisition as a pipeline catalyst
- Prefer a more defensive pharma position with established blockbuster revenue
- Are patient with post-COVID revenue normalisation as a temporary headwind, not a structural decline
- Want exposure to the mRNA platform's potentially transformative impact beyond COVID vaccines
- Believe mRNA-4157 personalised cancer vaccine could be a landmark product if Phase 3 confirms Phase 2 data
- Have a higher risk tolerance and are comfortable with meaningful cash burn during the pipeline build-out period
- View Moderna as a biotech platform investment rather than a traditional dividend pharma holding
| Metric | PFE | MRNA |
|---|---|---|
| AI scorei | N/A | N/A |
| AI ranki | N/A | N/A |
| Latest closei | N/A | N/A |
| Metric | PFE | MRNA |
|---|---|---|
| Market capi | N/A | N/A |
| Trailing P/Ei | N/A | N/A |
| Forward P/Ei | N/A | N/A |
| Price/Salesi | N/A | N/A |
| EV/Revenuei | N/A | N/A |
| Analyst targeti | N/A | N/A |
| Target upsidei | N/A | N/A |
| Metric | PFE | MRNA |
|---|---|---|
| Revenue growthi | N/A | N/A |
| Earnings growthi | N/A | N/A |
| EPS growthi | N/A | N/A |
| FCF margini | N/A | N/A |
| Operating margini | N/A | N/A |
| Profit margini | N/A | N/A |
| ROIC proxyi | N/A | N/A |
| Return on equityi | N/A | N/A |
| Dividend yieldi | N/A | N/A |
| Payout ratioi | N/A | N/A |
| Dividend growth streaki | N/A | N/A |
| Betai | N/A | N/A |
| Debt/equityi | N/A | N/A |
| Current ratioi | N/A | N/A |
| Quick ratioi | N/A | N/A |
Lower drawdown and smaller single-period drops generally indicate a smoother ride, though they do not guarantee lower future risk.
| Period | Metric | PFE | MRNA |
|---|---|---|---|
| 1Y | Growthi | N/A | N/A |
| CAGRi | N/A | N/A | |
| Volatilityi | N/A | N/A | |
| Sharpe ratioi | N/A | N/A | |
| Sortino ratioi | N/A | N/A | |
| Max drawdowni | N/A | N/A | |
| Current drawdowni | N/A | N/A | |
| Avg drawdowni | N/A | N/A | |
| Ulcer Indexi | N/A | N/A | |
| Max daily dropi | N/A | N/A | |
| Max wkly dropi | N/A | N/A | |
| 5Y | Growthi | N/A | N/A |
| CAGRi | N/A | N/A | |
| Volatilityi | N/A | N/A | |
| Sharpe ratioi | N/A | N/A | |
| Sortino ratioi | N/A | N/A | |
| Max drawdowni | N/A | N/A | |
| Current drawdowni | N/A | N/A | |
| Avg drawdowni | N/A | N/A | |
| Ulcer Indexi | N/A | N/A | |
| Max daily dropi | N/A | N/A | |
| Max wkly dropi | N/A | N/A | |
| 10Y | Growthi | N/A | N/A |
| CAGRi | N/A | N/A | |
| Volatilityi | N/A | N/A | |
| Sharpe ratioi | N/A | N/A | |
| Sortino ratioi | N/A | N/A | |
| Max drawdowni | N/A | N/A | |
| Current drawdowni | N/A | N/A | |
| Avg drawdowni | N/A | N/A | |
| Ulcer Indexi | N/A | N/A | |
| Max daily dropi | N/A | N/A | |
| Max wkly dropi | N/A | N/A |
| Category | PFE | MRNA |
|---|---|---|
| Company | Pfizer Inc. | Moderna, Inc. |
| Sector | Pharmaceuticals | Biotechnology |
| Industry | N/A | N/A |
| Core business | One of the world's largest pharmaceutical companies. Products include Paxlovid (COVID antiviral), Eliquis (blood thinner), Prevnar (pneumococcal vaccine), Vyndaqel (ATTR-cardiomyopathy), and an extensive oncology, rare disease, and vaccine pipeline. Recent acquisitions include Seagen (ADC oncology). | Biotechnology company focused on mRNA medicines. Currently markets Spikevax (COVID vaccine) and Mresvia (RSV vaccine for older adults). Extensive pipeline includes influenza, personalised cancer vaccines (with Merck), CMV, and rare disease programs. |
| Investor focus | Post-COVID revenue floor stabilisation, non-COVID business growth, Seagen ADC oncology ramp, pipeline productivity, cost restructuring, and dividend sustainability. | mRNA pipeline beyond COVID — RSV launch, flu vaccine combination, personalised cancer vaccine (mRNA-4157) data, and cash burn management against the product timeline. |
- Massive diversified pharmaceutical portfolio with multiple blockbuster drugs across therapeutic areas
- Seagen acquisition positions Pfizer as a leader in antibody-drug conjugate (ADC) oncology — a high-growth area
- One of the highest dividend yields among large-cap pharma, backed by substantial free cash flow
- Pioneered commercial mRNA medicine with COVID vaccines — unique platform expertise and manufacturing know-how
- mRNA-4157 personalised cancer vaccine (with Merck) is potentially the most significant oncology catalyst in years
- RSV vaccine approval establishes the second commercial mRNA product and validates the broader platform
- COVID product revenues (Paxlovid, Comirnaty) declined sharply from pandemic peaks and have been volatile
- Heavy M&A has increased debt levels, requiring successful execution to justify acquisition premiums
- Patent cliff risk on several major products over the next few years requires pipeline to fill revenue gaps
- COVID vaccine revenues continue declining — Moderna is burning significant cash as it awaits pipeline approvals
- mRNA-4157 cancer vaccine timeline risk — Phase 3 results needed to confirm Phase 2 signal before commercial reality
- Competition in RSV vaccine market (GSK, Pfizer Abrysvo) limits Mresvia's revenue upside
Compare more than two at a time
This page is a fixed writeup on PFE and MRNA. Our comparison engine is the interactive version: load up to five tickers, switch timeframes, and get the correlation, drawdown, and overlap analysis that a static page can't show.
Add three more names beside PFE and MRNA, mixing stocks and ETFs in the same table — useful when the real question is which of a whole peer group to own.
AI score, forward P/E, analyst target upside, operating margin, and revenue growth are scored head-to-head, with a running tally of which ticker leads on how many metrics.
Volatility, Sharpe and Sortino ratios, maximum, current, and average drawdown, Ulcer Index, and worst single-day and single-week drops across every timeframe.
Pairwise daily-return correlation for every combination, so you can see whether two holdings actually diversify each other or just move together.
A scatter plot of forward P/E against return on equity, plus drawdown and 30-day rolling volatility charts, to separate what is cheap from what is merely beaten down.
For ETFs, a top-holdings comparison that exposes hidden overlap between funds. Every comparison exports to CSV for your own spreadsheet work.
Two comparisons a week are free without an account. A 14-day trial removes the limit and adds AI price forecasts, stock rankings, saved watchlists, and the intrinsic value calculator — no credit card required.
Want deeper AI forecasts?
This comparison page is public and free forever. Subscribers can unlock saved watchlists, full AI rankings, detailed forecasts, and interactive analysis tools.
Full valuation workup with AI Score, Monte Carlo forecast, and bull/bear case — free preview, premium data from $3.99.